Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases
Obstetrics & Gynecology Science · 2019 · 62 (2) · 103
DOI: 10.5468/ogs.2019.62.2.103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obstetrics & Gynecology Science, 2019. Verfasst von E Sun Paik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Sungkyunkwan University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
ORCID-Profile: Jeong-Won Lee
Förderung
- Sungkyunkwan University
Zitieren
APA
Paik, E. S., Kang, J. H., Kim, J., Lee, Y. J., Choi, C. H., Kim, T. J., Kim, B. G., Bae, D. S., & Lee, J. W. (2019). Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases. Obstetrics & Gynecology Science, 62(2), 103. https://doi.org/10.5468/ogs.2019.62.2.103
Vancouver
Paik ES, Kang JH, Kim J, Lee YJ, Choi CH, Kim TJ, et al. Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases. Obstetrics & Gynecology Science. 2019;62(2):103. doi:10.5468/ogs.2019.62.2.103
BibTeX
@article{Paik2019,
author = {Paik, E Sun and Kang, Jae Hong and Kim, Jihye and Lee, Yeon-Joo and Choi, Chel Hun and Kim, Tae-Joong and Kim, Byoung-Gie and Bae, Duk-Soo and Lee, Jeong-Won},
title = {Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases},
journal = {Obstetrics & Gynecology Science},
year = {2019},
volume = {62},
number = {2},
pages = {103},
doi = {10.5468/ogs.2019.62.2.103}
}
EUVIMED